The efficacy of levonorgestrel intrauterine systems for endometrial protection: A systematic review

Climacteric

Volumn 14, Issue 6, 2011, Pages 622-632

  Wan, Y L ^a   Holland, C ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

chemoprevention; endometrial neoplasm; endometrial polyps; hyperplasia; intrauterine device; intrauterine system; levonorgestrel; mirena

Indexed keywords

ESTRADIOL; ESTROGEN; GESTAGEN; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE;

CANCER RISK; DRUG EFFICACY; ENDOMETRIAL DISEASE; ENDOMETRIUM HYPERPLASIA; ENDOMETRIUM POLYP; ESTROGEN THERAPY; HIGH RISK PATIENT; HUMAN; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW;

CONTRACEPTIVE AGENTS, FEMALE; ENDOMETRIAL HYPERPLASIA; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; INTRAUTERINE DEVICES, MEDICATED; LEVONORGESTREL; RISK FACTORS; TREATMENT OUTCOME;

EID: 81755178295     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.3109/13697137.2011.579650     Document Type: Review

References (48)

1. Bray F, Dos Santos Silva I, Moller H, Weiderpass E. Endometrial cancer incidence trends in Europe: underlying determinants and prospects for prevention. Cancer Epidemiol, Biomarkers Prevention 2005;14:1132-42 (Pubitemid 40656458)
2. Ferlay JSH, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide. IARC CancerBase No 10, 2010 [cited; Available from: http://globocan. iarc.fr/]
3. Elwood JM, Cole P, Rothman KJ, Kaplan SD. pidemiology of endometrial cancer. J Natl Cancer Instit 1977;59:1055-60
4. La Vecchia C, Franceschi S, Decarli A, Gallus G, Tognoni G. Risk factors for endometrial cancer at different ages. J Natl Cancer Instit 1984;73:667-71 (Pubitemid 14000199)
5. Cogliano V, Grosse Y, Baan R, Straif K, Secretan B, El Ghissassi F. Carcinogenicity of combined oestrogen-progestagen contraceptives and menopausal treatment. Lancet Oncol 2005;6:552-3 (Pubitemid 41051931)
6. Bergman L, Beelen ML, Gallee MP, Hollema H, Benraadt J, van Leeuwen FE. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres ' ALERT Group. Assessment of Liver and Endometrial Cancer Risk following Tamoxifen. Lancet 2000;356:881-7
7. Humphrey MM, Apte SM. The use of minimally invasive surgery for endometrial cancer. Cancer Control 2009;16:30-7
8. Fader AN, Arriba LN, Frasure HE, von Gruenigen VE. Endometrial cancer and obesity: epidemiology, biomarkers, prevention and survivorship. Gynecol Oncol 2009;114:121-7
9. Siiteri PK. Steroid hormones and endometrial cancer. Cancer Res 1978;38:4360-6 (Pubitemid 9054232)
10. Key TJ, Pike MC. The dose-effect relationship between - unopposed ' oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk. Br J Cancer 1988;57:205-12 (Pubitemid 18085407)
11. Good RG, Moyer DL. Estrogen-progesterone relationships in the development of secretory endometrium. Fertil Steril 1968;19: 37-49
12. Sherman ME. Theories of endometrial carcinogenesis: a multidisciplinary approach. Mod Pathol 2000;13:295-308 (Pubitemid 30207514)
13. Lacey JV Jr, Ioffe OB, Ronnett BM, et al . Endometrial carcinoma risk among women diagnosed with endometrial hyperplasia: the 34-year experience in a large health plan. Br J Cancer 2008;98: 45-53
14. Lacey JV Jr, Chia VM. Endometrial hyperplasia and the risk of progression to carcinoma. Maturitas 2009;63:39-44
15. Gruber SB, Thompson WD. A population-based study of endometrial cancer and familial risk in younger women. Cancer and Steroid Hormone Study Group. Cancer Epidemiol Biomarkers Prev 1996;5:411-17 (Pubitemid 26182653)
16. Aarnio M, Mecklin JP, Aaltonen LA, Nystrom-Lahti M, Jarvinen HJ. Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome. Int J Cancer 1995; 64:430-3 (Pubitemid 26048907)
17. Vasen HF, Wijnen JT, Menko FH, et al . Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology 1996;110:1020-7 (Pubitemid 26113739)
18. Manchanda R, Menon U, Michaelson-Cohen R, Beller U, Jacobs I. Hereditary non-polyposis colorectal cancer or Lynch syndrome: the gynecological perspective. Curr Opin Obstet Gynecol 2009;21:31-8
19. Neven P, Vergote I. Should tamoxifen users be screened for endometrial lesions? Lancet 1998;351:155-7 (Pubitemid 28037001)
20. Gadducci A, Spirito N, Baroni E, Tana R, Genazzani AR. The fertility-sparing treatment in patients with endometrial atypical hyperplasia and early endometrial cancer: a debated therapeutic option. Gynecol Endocrinol 2009;25:683-91
21. Lethaby A, Farquhar C, Sarkis A, Roberts H, Jepson R, Barlow D. Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding. Cochrane database of systematic reviews (Online) 2000(2):CD000402
22. Peto odds ratio method. C ochrane Handbook for Systematic Reviews of Interventions , Version 5.0.2 [updated September 2009]. Chapter 9.4.4.2. [cited; Available from: http://www. cochrane-handbook.org/]
23. Volpe A, Botticelli A, Abrate M, et al . An intrauterine progesterone contraceptive system (52 mg) used in pre- and peri-menopausal patients with endometrial hyperplasia. Maturitas 1982; 4:73-9 (Pubitemid 12047470)
24. Suvanto-Luukkonen E, Malinen H, Sundstrom H, Penttinen J, Kauppila A. Endometrial morphology during hormone replacement therapy with estradiol gel combined to levonorgestrel-releasing intrauterine device or natural progesterone. Acta Obstet Gynecol Scand 1998;77:758-63 (Pubitemid 28372148)
25. Intrauterine levonorgestrel and observation or observation alone in preventing atypical endometrial hyperplasia and endometrial cancer in women with hereditary non-polyposis colorectal cancer or Lynch Syndrome. National Institute of Health: Clinical Trials. gov [cited 17th July 2009]; Available from: http://clinicaltrials. gov/ct2/show/record/NCT00566644
26. A randomized, controlled, comparative study of a levonorgestrel intrauterine system for the prevention of endometrial cancer in patients aged 40-50 with BMI greater than 35. National Instititue of Health: Clinical Trials.gov. [cited 17th July 2009]; Available from: http://clinicaltrials.gov/ ct2/show/record/NCT00161226
27. Suhonen SP, Holmstrom T, Allonen HO, Lahteenmaki P. Intrauterine and subdermal progestin administration in postmenopausal hormone replacement therapy. Fertil Steril 1995;63:336-42
28. Antoniou G, Kalogirou D, Karakitsos P, Antoniou D, Kalogirou O, Giannikos L. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints versus estradiol-releasing vaginal ring with a vaginal progesterone suppository: clinical and endometrial responses. Maturitas 1997; 26:103-11 (Pubitemid 27138843)
29. Raudaskoski TH, Lahti EI, Kauppila AJ, Apaja-Sarkkinen MA, Laatikainen TJ. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: clinical and endometrial responses. Am J Obstet Gynecol 1995;172:114-19
30. Raudaskoski T, Tapanainen J, Tomas E et al. Intrauterine 10 μ and 20 μ levonorgestrel systems in postmenopausal women receiving oral oestrogen replacement therapy: clinical, endometrial and metabolic response. BJOG 2002;109:136-44 (Pubitemid 37345123)
31. Boon J, Scholten PC, Oldenhave A, Heintz AP. Continuous intrauterine compared with cyclic oral progestin administration in perimenopausal HRT. Maturitas 2003;46:69-77 (Pubitemid 37098293)
32. Andersson K, Mattsson LA, Rybo G, Stadberg E. Intrauterine release of levonorgestrel - a new way of adding progestogen in hormone replacement therapy. Obstet Gynecol 1992;79:963-7
33. Archer DF. The effect of the duration of progestin use on the occurrence of endometrial cancer in postmenopausal women. Menopause 2001;8:245-51 (Pubitemid 32645957)
34. Riphagen FE. Intrauterine application of progestins in hormone replacement therapy: a review. Climacteric 2000;3:199-211
35. Gardner FJ, Konje JC, Bell SC, et al . Prevention of tamoxifen induced endometrial polyps using a levonorgestrel releasing intrauterine system long-term follow-up of a randomised control trial. Gynecol Oncol 2009;114:452-6
36. Suvanto-Luukkonen E, Sundstrom H, Penttinen J, Laara E, Pramila S, Kauppila A. Percutaneous estradiol gel with an intrauterine levonorgestrel releasing device or natural progesterone in hormone replacement therapy. Maturitas 1997;26:211-17 (Pubitemid 27209953)
37. Vereide AB, Arnes M, Straume B, Maltau JM, Orbo A. Nuclear morphometric changes and therapy monitoring in patients with endometrial hyperplasia: a study comparing effects of intrauterine levonorgestrel and systemic medroxyprogesterone. Gynecol Oncol 2003;91:526-33 (Pubitemid 38388145)
38. Orbo A, Arnes M, Hancke C, Vereide AB, Pettersen I, Larsen K. Treatment results of endometrial hyperplasia after prospective D-score classifi cation: a follow-up study comparing effect of LNG-IUD and oral progestins versus observation only. Gynecol Oncol 2008;111:68-73
39. Gardner FJ, Konje JC, Abrams KR, et al . Endometrial protection from tamoxifen-stimulated changes by a levonorgestrel-releasing intrauterine system: a randomised controlled trial. Lancet 2000;356:1711-17
40. Chan SS, Tam WH, Yeo W, et al. A randomised controlled trial of prophylactic levonorgestrel intrauterine system in tamoxifentreated women. BJOG 2007;114:1510-15 (Pubitemid 350077441)
41. Kesim MD, Aydin Y, Atis A, Mandiraci G. Long-term effects of the levonorgestrel-releasing intrauterine system on serum lipids and the endometrium in breast cancer patients taking tamoxifen. Climacteric 2008;11:252-7
42. Varma R, Sinha D, Gupta JK. Non-contraceptive uses of levonorgestrel- releasing hormone system (LNG-IUS) - a systematic enquiry and overview. Eur J Obstet Gynecol Reprod Biol 2006;125:9-28
43. Sturdee DW, Rantala ML, Colau JC, Zahradnik HP, Riphagen FE. The acceptability of a small intrauterine progestogen-releasing system for continuous combined hormone therapy in early postmenopausal women. Climacteric 2004;7:404-11 (Pubitemid 40021798)
44. Wollter-Svensson LO, Stadberg E, Andersson K, Mattsson LA, Odlind V, Persson I. Intrauterine administration of levonorgestrel 5 and 10 μ/24 hours in perimenopausal hormone replacement therapy. A randomized clinical study during one year. Acta Obstet Gynecol Scand 1997;76:449-54 (Pubitemid 27226267)
45. Lyytinen HK, Dyba T, Ylikorkala O, Pukkala EI. A case-control study on hormone therapy as a risk factor for breast cancer in Finland: Intrauterine system carries a risk as well. Int J Cancer 2010;126:483-9
46. Chin J, Konje JC, Hickey M. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen. Cochrane Database of Systematic Reviews (Online) 2009(4):CD007245
47. Luukkainen T, Toivonen J. Levonorgestrel-releasing IUD as a method of contraception with therapeutic properties. Contraception 1995;52:269-76
48. Backman T. Benefi t-risk assessment of the levonorgestrel intrauterine system in contraception. Drug Saf 2004;27:1185-204 (Pubitemid 40066081)